Headlands Technologies LLC Raises Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Headlands Technologies LLC raised its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 213.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,830 shares of the company’s stock after buying an additional 10,095 shares during the quarter. Headlands Technologies LLC’s holdings in GoodRx were worth $65,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in GDRX. Jacobs Levy Equity Management Inc. grew its holdings in GoodRx by 303.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock valued at $4,936,000 after buying an additional 798,261 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in GoodRx in the 4th quarter valued at $2,500,000. Dimensional Fund Advisors LP grew its holdings in shares of GoodRx by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock worth $9,264,000 after purchasing an additional 369,553 shares during the period. Two Sigma Investments LP grew its holdings in shares of GoodRx by 98.1% during the 4th quarter. Two Sigma Investments LP now owns 722,374 shares of the company’s stock worth $3,359,000 after purchasing an additional 357,674 shares during the period. Finally, Two Sigma Advisers LP grew its holdings in shares of GoodRx by 69.1% during the 4th quarter. Two Sigma Advisers LP now owns 754,000 shares of the company’s stock worth $3,506,000 after purchasing an additional 308,000 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $3.50 on Wednesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. GoodRx Holdings, Inc. has a fifty-two week low of $3.31 and a fifty-two week high of $8.80. The firm has a market capitalization of $1.25 billion, a PE ratio of 35.00, a price-to-earnings-growth ratio of 1.43 and a beta of 1.24. The stock’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $4.53.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $203.07 million for the quarter, compared to analyst estimates of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.08 EPS. As a group, equities research analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.17% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GDRX. UBS Group lowered their price target on GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Wells Fargo & Company lowered their price target on GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. The Goldman Sachs Group lowered their target price on GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Raymond James Financial cut GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $6.00 target price on shares of GoodRx in a report on Monday. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.18.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.